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INTRODUCTION 
Asthma is characterized by chronic inflammation of the
airways, associated with inflammatory cells, including
eosinophils, mast cells, basophils, macrophages, and T
helper (TH) cells. These cells are involved in development
of airway hyperresponsiveness (AHR), bronchoconstric-
tion, mucus secretion, and remodeling by releasing
inflammatory mediators, such as chemokines, growth fac-
tors, lipid mediators, and chemical mediators. Then, the
complex pathogenesis of asthma is contributed to by vari-
ous cellular responses, based on the dysregulated interac-
tion between the innate and adaptive immune systems.
Recent evidence suggests that prostaglandin D2 (PGD2),
a major prostanoid, may play an important role in orches-
trating interactions between mast cells, TH2 cells, eosinophils,
and dendritic cells.
TH2 immune response in asthma
Allergic diseases are characterized by elevated serum
immunoglobulin (Ig) E levels and hypersensitivity to nor-
mally innocuous antigens as allergens. A particular aller-
gen first encounters antigen-processing cells (APC), such
as dendritic cells or macrophages, directly. The allergen
captured by the APC is processed and presented to CD4
+ T
cells. CD4
+ T cells are polarized into distinct types of TH
cells. Major TH cell subsets include TH1, TH2, and TH17,
and also recently discovered TH9 and TFH cells. Each TH
cell subset expresses a characteristic cytokine profile that
generates a characteristic inflammatory response in aller-
gic diseases, such as bronchial asthma. Among these TH
cells, TH2 cells are believed to play a critical pathogenic
role in allergic inflammation. TH2 cells produce cytokines,
interleukin (IL)-4, IL-5, IL-6, IL-9, and IL-13, although
they may also result from other cell types. Patients with
allergic asthma have eosinophilic inflammation in the
lung, in parallel with increased TH2 cytokines, as well as
elevated serum IgE. IL-4 and IL-13 are representative
TH2-type cytokines that play a crucial role in human aller-
gic disease. IL-4 promotes differentiation and prolifera-
tion in TH2 cells, whereas IL-13 mediates AHR and mucus
hyperproduction [1,2]. IL-5 is a cytokine that is highly spe-
cific to eosinophil activation and recruitment and con-
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tributes to eosinophilic inflammation, a prominent patho-
logical feature in most asthma. TH2 cytokines also trigger
the production of chemokines, including CCL11/eotaxin,
CCL17/TARC, and CCL22/macrophage-derived
chemokine (MDC), in tissue fibroblasts or epithelial cells,
promoting the infiltration of inflammatory cells, such as
eosinophils and TH2 cells into sites exposed to allergens.
Importantly, IL-4 and IL-13 stimulate immunoglobulin
class switching, leading to IgE production, which binds to
its high-affinity receptor (FcεRI) on the surface of mast
cells or basophils. The association of captured allergens
with IgE bound to FcεRI on the cell surface activates sig-
nal transduction in these cells and rapidly leads to the
release of inflammatory cytokines and chemical media-
tors, such as histamine and leukotrienes in mast cells and
basophils and PGD2 in mast cells. Furthermore, particular
interest has been generated in novel epithelial cell-derived
cytokines including thymic stromal lymphopoietin
(TSLP), IL-25, and IL-33, which have all been implicated
in promoting TH2 cytokine responses, and their ability to
influence innate and adaptive immune responses associat-
ed with TH2 cytokine-mediated inflammation in airways.
Recent evidence suggests that coordinated expression and
cross-regulation between TSLP, IL-25, and IL-33 are cru-
cial events for developing TH2 cell-mediated airway
immune responses in asthma. In contrast, PGD2 modu-
lates airway physiology by causing bronchoconstriction,
vasodilation, increases in capillary permeability, and
mucous production in asthma. These functions are well-
known effects that may facilitate transendothelial migra-
tion of inflammatory cells, such as eosinophils, mast cells,
lymphocytes, and monocytes, during allergic inflamma-
tion. In addition to such classical effects, novel properties
of PGD2 include TH2 inflammation in allergic diseases
(Fig. 1). 
PGD2 and its metabolites
PG production begins with the liberation of arachidonic
acid from membrane phospholipids by phospholipase A2
in response to inflammatory stimuli. Arachidonic acid is
converted to PGH2 by the cyclooxygenase enzymes COX-1
and COX-2. PGH2 is a common precursor of several PGs,
including PGD2, which is generated by the actions of two
PG synthases, known as the lipocalin-type PGD synthase
(L-PGDS), primarily expressed in brain, heart, and adi-
pose tissue, and the hematopoietic PGD synthase (H-
PGDS), mainly expressed in mast cells, macrophages,
dendritic cells (DCs), and TH2 cells. It is generally thought
that COX-1 is expressed constitutively in most tissues of
the body and functions to maintain homeostatic process-
es, such as mucus secretion. In contrast, COX-2 is primar-
ily an inducible enzyme, involved mainly in the regulation
of inflammation [3]. PGD2 is a major product from COX-
catalyzed reactions in a variety of tissues and cells, includ-
ing those of the immune system, such as T cells, DCs,
macrophages, mast cells, and platelets.
PGD2 production in asthma
Fujitani et al. [4] generated transgenic mice overex-
pressing lipocalin-like PGD synthetase in the lung and
subjected them to ovalbumin (OVA)-induced pulmonary
allergic inflammation. They found elevated IL-4 and IL-5
concentrations and increased eosinophilic infiltration in
bronchoalveolar-lavage fluid (BALF) in these mice.
Mandal et al. [5] reported that a reduction in PGD2 syn-
thesis, induced by uteroglobin, an anti-inflammatory pro-
tein, was associated with reduced allergic inflammation.
Furthermore, PGD2 nebulization before aerosol Ag chal-
lenge enhanced TH2 inflammatory responses, including
eosinophilia, and leads to the development of AHR [6].
Collectively, these findings appear to substantiate the pro-
posal that PGD2 acts as an important mediator in allergic
asthma.
Activated mast cells contribute to asthmatic pulmonary
inflammation by producing a variety of chemical media-
tors and cytokines. During allergic responses, PGD2 is
released in large amounts by mast cells during asthmatic
attacks in humans. DCs [7] and TH2 cells [8] also produce
PGD2. Furthermore, fibroblasts, bronchial smooth muscle
cells, and airway epithelial cells are also thought to pro-
duce PGD2, precipitating pulmonary inflammation. It is
well established that the presence of an allergen triggers
PGD2 production in sensitized individuals. In individuals
with asthma, a bronchial allergen challenge leads to rapid
PGD2 production, which can be detected in the BALF
within minutes, reaching biologically active levels at least
150-fold higher than pre-allergen levels [9]. A local anti-
gen challenge also stimulates PGD2 production in the
nasal mucosa of patients with allergic rhinitis [10] and in
the skin of patients with atopic dermatitis (AD) [11].
Several lines of evidence support the view that mast cells
are the principal sources of PGD2 at allergic inflammation
sites. Cell fractionation studies have shown that PGD2 is
produced predominantly by mast cells [12], and mast cell10 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
activation is a requirement for PGD2generation in chopped
human lung parenchyma [13]. Thus, mast cells are
responsible for the bulk of PGD2 production in the allergic
setting. PGD2 produced by mast cells may provide an
essential link between early-phase and late-phase allergic
responses by initiating cellular processes that lead to the
recruitment and activation of TH2 cells and eosinophils
with associated pathophysiological effects.
PGD2-related receptors
Among PG receptors, D prostanoid receptor (DP)/DP1,
DP2/chemoattractant receptor homologous molecule
expressed on TH2 cells (CRTH2), and thromboxane A2
receptor (TP) belong to a family of seven-transmembrane
G-protein-coupled receptors (GPCRs), mediating the bio-
logical effects of both PGD2 and its metabolites. In con-
trast, peroxisome proliferator-activated receptor (PPAR)-
γ is a nuclear receptor for PGD2 metabolites. DP, TP, and
PPAR-γ are present in various types of hematological and
non-hematological cells [14,15]. In contrast, human
CRTH2 has been specifically identified on hematological
cells [16], although the tissue expression pattern of
CRTH2 in humans differs from that in rodents [17].
DP is the most studied PGD2 receptor and its activation
leads to Gs-mediated elevation in cAMP. DP is activated
by PGD2 and its metabolites, including ∆
12-PGD2 and PGJ2.
Such activation by DP-selective agonists, such as BW245C,
promotes relaxation of both vascular and airway smooth
muscle, leading to vasodilatation and bronchodilatation,
respectively [18]. DP is also expressed by platelets, in
which its activation is linked to an anti-aggregatory func-
tion [19]. DP plays both anti-inflammatory and proinflam-
matory roles. Accumulation of cAMP is generally associat-
ed with the inhibition of effector cell function in lympho-
cytes, such as TH1 cells and natural killer cells, and other
immune cells, [20]. Consistent with this, DP-mediated
signals also suppress cell migration and/or the activation
of eosinophils, basophils, netrophils, DCs, and fibroblasts
[16,21-24]. Inhalation of a selective DP agonist suppresses
Figure 1. TH2 immune response in asthma. Proposed scheme showing TH2 cell immunity in the pathogenesis of bronchial asthma.
TH2 cells play an important role, organizing the characteristic inflammatory response, involving mast cells, basophils, and eosinophils.
Recent evidence suggests that coordinated expression and cross-regulation between thymic stromal lymphopoietin (TSLP), interleukin
(IL)-25, and IL-33 are crucial events for developing TH2 cell-mediated airway immune responses during asthma. These inflammatory
cells also produce TH2-type cytokines, indicating that these cells and TH2 cells interact with each other to promote TH2 type inflamma-
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asthma in a murine model by down-modulating lung DC
function and inducing regulatory T cells. In contrast, DP is
expressed by epithelial cells, fibroblast cells, and certain
leukocyte populations [25-28] including monocytes, DCs,
T cells, basophils, eosinophils, and mast cells, where it has
been suggested to control several functions including the
production of cytokines and lipid mediators. PGD2 syner-
gizes with tumor necrosis factor via DP receptors to pro-
mote CCL2/MCP-1 and IL-8 production in monocytic
cells [29]. urthermore, Matsuoka et al. [30] examined the
role of DP in asthma by studying DP receptor-deficient
mice in a model of OVA-induced allergic inflammation.
Loss of DP did not affect the primary immune response,
because similar serum total and OVA-specific IgE concen-
trations were observed in immunized wild-type and DP-
deficient mice. However, the concentrations of TH2
cytokines, such as IL-4, IL-5, and IL-13, were significantly
reduced, and lymphocyte and eosinophil accumulations in
BALF were significantly suppressed in DP-deficient mice,
compared with wild-type mice after the OVA challenge.
While extensive cell infiltration and occasional bronchus-
associated lymphoid tissue formation were consistently
found in the lungs of all OVA-challenged wild-type mice,
minimal cell infiltration was detected in the lungs of OVA-
challenged DP-deficient mice. In contrast to wild-type
mice, few mucus-containing cells were detected in the air-
ways of DP-deficient mice. Moreover, whereas the OVA
challenge significantly increased airway sensitivity to
acetylcholine in wild-type mice, a minimal increase was
detected in DP-deficient mice. Thus, PGD2 appears to act
on DP and play an important role eliciting certain key fea-
tures of allergic asthma. This has been confirmed by other
experiments. Arimura et al. [31] administered the DP
antagonist S-5751 orally to a similar guinea pig model of
OVA-induced allergic asthma and found that it signifi-
cantly alleviated eosinophil infiltration into the lung.
Moreover, an association of DP promoter and gene poly-
morphisms with asthma has been detected in humans
[32]. Thus, a DP-mediated PGD2 effect is expected to be
involved in allergic and/or asthmatic responses.
CRTH2 was originally identified as an orphan receptor,
expressed on type 2 polarized lymphocytes (TH2 and Tc2)
[33], basophils, eosinophils [34], and monocytes [35], and
mediates its effects by promoting the activation and
chemotaxis of TH2 cells, eosinophils, basophils [16], and
monocytes [35]. Despite binding to PGD2 with a similar
affinity to DP, CRTH2 is not structurally related to DP and
signals through a different mechanism. The effects of
CRTH2 are mediated through a Gαi-dependent increase
in intracellular calcium levels and a reduction in intracel-
lular cAMP levels, indicating that CRTH2-mediated sig-
nals are predominantly proinflammatory. Unlike the
prostanoid DP receptor, CRTH2 is a member of the
chemoattractant receptor family, sharing higher sequence
homology to the fMLP and C5a receptors than to the
prostanoid receptor family [16]. The PGD2 metabolites, 13,
14-dihydro-15-keto PGD2 (DK-PGD2), ∆
12 PGD2, PGJ2, ∆
12-
PGJ2, 15d-PGJ2, and 9α, 11β-PGF2 bind to CRTH2
[16,17,36] and activate eosinophils [36-38]. PGF2α is a
stereoisomer of 9α, 11β-PGF2, produced from PGH2 by the
action of PGF synthase and from PGE2 by the action of
PGE9-ketoreductase, independently of PGD synthetase.
PGF2 is also implicated in CRTH2 signaling in the pres-
ence or absence of PGD2 production [39]. CRTH2 can also
be activated by the thromboxane A2 metabolite, 11-dehy-
dro-TBX2 [40]. The existence of these CRTH2 agonists
suggests that this receptor may be of physiological impor-
tance even in the absence of basal PGD2 production.
Ramatroban (BAYu3405) is an effective CRTH2 antago-
nist [41]. Ramatroban was originally identified as a TP
antagonist, but it has been discovered that this drug binds
to the CRTH2 receptor with moderate affinity (its antago-
nistic activity against CRTH2 is about 10-fold lower than
that against TP) and blocks responses to the selective
CRTH2 agonist DK-PGD2, in vitro and in vivo [41,42].
Uller et al. [43] studied the specificity of CRTH2 antago-
nism by TM30089, which is closely related structurally to
dual TP/CRTH2 antagonists in mice. They assessed the
inhibition of asthma-like pathological characteristics.
Studies with these antagonists suggest that CRTH2 plays
an important role mediating airway inflammation in
response to an allergic challenge in both the guinea pig
nasal mucosa [44] and mouse airway [45]. In humans,
CRTH2 activation is responsible, at least in part, for the
implications of PGD2 in asthma and inflammatory dis-
eases [46,47] as well as allergic rhinitis [48] Thus, CRTH2
is considered to play an important role in allergic inflam-
mation, similar to DP.
PGD2 enhances or suppresses inflammation by acting
on different receptors expressed by hematopoietic and
non-hematopoietic cells. Several cells of the immune sys-
tem express both DP and CRTH2, which are coupled to
apparently opposing signaling pathways. Because DP acti-
vation is often associated with inhibition of immune cell
function [20], whereas CRTH2 activation leads to
immune cell activation [20], it is tempting to hypothesize12 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
that these two PGD2 receptors collaborate to regulate
inflammatory cell functions by different mechanisms.
Although many immune cells coexpress DP and CRTH2,
CRTH2-mediated signals often predominate over DP-
mediated signals when cells are exposed to the non-selec-
tive agonist PGD2 [17,21,49], which binds to CRTH2 and
DP with equal affinity [23,50]. One possible explanation
for this observation may be the lower expression level of
DP compared with that of CRTH2. Indeed, attempts to
quantify DP and CRTH2 transcripts in immune cells, such
as basophils, eosinophils, and TH2 cells, and in human air-
way smooth muscle cells have revealed significantly lower
DP expression [4,21,24,28,51,52]. Because both DP and
CRTH2 expression levels can be upregulated and down-
regulated by inflammatory stimuli [4,53,54], it is conceiv-
able that the overall effect of PGD2 depends on the expres-
sion level of PGD2receptors in a given cell.
Role of PGD2 in TH2 cell functions
TH cells, particularly those of the TH2 cell-related
inflammatory response, have a crucial role in asthma
pathogenesis. The TH2 type response is coordinated by
TH2 cell differentiation and a modification of TH2 cell
functions, such as cytokine production, recruitment, pro-
liferation, survival, and apoptosis. Differentiation into
each TH cell subset is delicately controlled in vivo by inter-
actions with DCs. Airway DCs [25-27] express both
CRTH2 and DP. The role of CRTH2 in DC function
remains unclear, whereas DP-mediated regulation of DCs
has been demonstrated in several studies. PGD2 suppress-
es the activation of DCs and prevents their migration into
the T cell areas of draining lymph nodes [25]. This effect is
mediated by DP. Indeed, it is mimicked by the DP-selec-
tive agonist BW 245C, but not by the CRTH2-selective
agonist DK-PGD2 [25]. This suppressive mechanism by
DP may underlie the inhibition of TH2 cell differentiation.
Furthermore, inhaling a selective DP agonist suppresses
the cardinal features of asthma by targeting the functions
of lung DCs [55]. Interestingly, an increase in Foxp3
+CD4
+
regulatory T cells was observed in mice treated with a DP
agonist or DP-agonist-treated DCs, which suppressed
inflammation in an IL-10-dependent manner. In contrast,
it has been proposed that the DP-mediated inhibition of
the production of TH1-inducing cytokines, such as IL-12
[26], by DCs favors T-cell development towards the TH2
phenotype [27]. This effect has been observed in preclini-
cal models, such as TH1-dependent delayed-type hyper-
sensitivity reactions [56], although additional mecha-
nisms involving PPAR activation have been proposed in
some cases.
Interestingly, DCs can themselves produce PGD2, which
has been suggested to be involved in PGD2-mediated syn-
thesis of CCL22/MDC, a chemoattractant for TH2 cells, in
interferon (IFN)-γ-treated human keratinocytes [57]. DCs
not only function as target of PGD2, but also may play an
important role in modulating local immunity and inflam-
mation though self-producing PGD2.
Among human TH cell subsets, CRTH2 is preferentially
expressed on TH2 cells, and is the most reliable marker to
identify human CD4
+ TH2 memory cells [32,58]. In con-
trast, DP is expressed on both TH1 and TH2 cells. Importantly,
CRTH2 mediates the migration of TH2 cells towards PGD2
[16] and delays TH2 cell apoptosis. Recently, human
CRTH2
+ TH2 memory cells were reported to be main-
tained by TSLP-activated DC. Furthermore, CRTH2
+CD4
+
TH2 memory cells activated by TSLP-DCs undergo further
TH2 polarization and express prostaglandin PGD2 syn-
thase. Thus, in cooperation with DC-derived PGD2, TH2
cell-derived PGD2 may promote further accumulation of
TH2 cells to the inflamed tissue [59] by positive feedback
mechanisms, causing persistent inflammation and dam-
age to the asthma airways.
Another notable role of PGD2 is regulating the produc-
tion of proinflammatory cytokines in TH2 cells [28,51].
Tanaka et al. have shown that human CD4
+ and CD8
+ T
cells producing IFN-γ and IL-2 are reduced in number by
DP-mediated signals [28], whereas CRTH2-mediated sig-
nals enhance the ability of human TH2 cells to produce IL-
2, IL-4, IL-5, and IL-13, an effect that was inhibited by
ramatroban [51]. This PGD2-mediated effect on cytokine
production by TH2 cells is mimicked by the selective
CRTH2 agonist DK-PGD2 [51]. CRTH2-mediated PGD2
effects were dominantly observed on CRTH2
+ TH2 cells,
compared with DP-mediated effects after treatment with
BW 245C, resulting in the attenuated production of
cytokines by TH2 cells [28]. Furthermore, activation of
TH2 cells in response to supernatants from immunologi-
cally activated human mast cells is mediated by PGD2,
through an action on CRTH2 [60]. Together, these find-
ings suggest that PGD2 favors TH2 functions through
CRTH2 for recruiting TH2 cells to sites of allergic inflam-
mation and for driving TH2-cytokine production, while
restraining TH1 functions via DP, which may contribute to
the development of TH2-dominated status during allergic
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biased towards TH2 cells, unlike humans [61], and the
functions of CRTH2 may differ between mice and
humans. Indeed, IL-4 and IFN-γ production was not
affected in CRTH2-deficient mice. These results do sug-
gest that the cytokines and chemokines regulated by
CRTH2 differ between mice and humans. Furthermore,
Chevalier et al. [62] found that CRTH2-deficient mice
show enhanced eosinophil recruitment into the lung,
compared with their wild-type littermates, and showed
that CRTH2-deficient T cells produced significantly higher
amounts of IL-5 and IL-3 in vitro. These results suggest a
non-redundant role for CRTH2 in restricting eosinophilia
and allergic responses in vivo. The authors suggested that
one possible explanation for their findings was that
CRTH2 promoted IL-5 production early on, and that the
inhibitory pathway was subsequently turned on. In con-
trast, Satoh et al. [63] reported that allergic skin inflam-
mation and IgE production were significantly diminished
in CRTH2-deficient mice, consistent with the results of
the pharmacological studies with human cells discussed
above. Studies of allergic responses in mice in which
CRTH2 has been genetically deleted have so far produced
conflicting results. The CRTH2-mediated effects of PGD2
may interact in a complex fashion, with redundant roles
and non-redundant roles, in stimulating cytokine produc-
tion and allergic inflammation. These findings suggest
that CRTH2 might be a highly promising therapeutic tar-
get, because CRTH2 blockade by small-molecule antago-
nists is likely to attenuate TH2 activity with respect to
accumulation at sites of inflammation, cytokine release,
and survival in tissue (Fig. 2).
Role of PGD2 in nonhematopoietic-cell functions
Although minimal expression of DP was detected in the
lungs of non-immunized mice, an airway OVA challenge
markedly enhanced DP receptor expression [30].
Immunoelectron microscopy, using an antibody to mouse
DP, revealed that the DP receptor is highly expressed on
ciliated and non-ciliated epithelial cells of the bronchioles
Figure 2. Hypothetical mechanism for developing asthmatic airway inflammation promoted by prostaglandin D2 (PGD2). PGD2 has
been recognized as an important mediator of asthmatic airway inflammation. Critical effects of receptors, in particular the D-
prostanoid receptor (DP) and chemoattractant receptor homologous molecule expressed on TH2 cells (CRTH2), are immune and
inflammatory regulators of various immune cells, particularly T cells, basophil, eosinophils, mast cells, dendritic cells, and bronchial
epithelial cells. CRTH2 signaling is involved in accelerating allergic inflammation by promoting chemotaxis and upregulating cytokine
production. In contrast, the effect of DP signaling is mainly as an immune suppressor. MDC, macrophage-derived chemokine; TSLP,
thymic stromal lymphopoietin; IL, interleukin.and type II alveolar epithelial cells. Moderate expression
was also found in type I alveolar epithelial cells and
inflammatory white blood cells [30]. Airway epithelium
has been proposed to be a source of proinflammatory
cytokines and chemokines during asthma pathogenesis
[64]. These findings suggest the following model for PGD2
in asthma: mast cell-derived PGD2 acts at DP receptors in
the epithelium and stimulates the production and release
of cytokines and chemokines to induce airway inflamma-
tion, obstruction, and hyper-reactivity. Chiba et al. report-
ed that PGD2 induced IL-8 and granulocyte-macrophage
colony-stimulating factor by bronchial epithelial cells in
association with mitogen-activated protein (MAP)/ERK
and p38 MAP kinase activation via a CRTH2-independent
pathway [65]. To further investigate the involvement of
bronchial epithelial cells, Honda et al. [6] established a
novel experimental model of asthma that permitted the
direct assessment of the role of PGD2 in airway inflamma-
tion. Antigen-sensitized mice were exposed to aerosolized
PGD2 1 day before challenge with low-dose aerosolized
antigen. The results showed that not only the numbers of
eosinophils, lymphocytes, and macrophages, but also the
levels of IL-4 and IL-5 in BALF were higher in PGD2-pre-
treated mice than in control mice. Moreover, the expres-
sion of MDC, a TH2 cell chemoattractant, was higher in
PGD2-pretreated mice than in controls. Furthermore, the
authors showed that injecting anti-MDC antibody into
PGD2-pretreated mice markedly inhibited inflammatory
cell infiltration as well as TH2 cytokine production after
antigen challenge. These results indicate that PGD2 accel-
erates TH2 type inflammation by inducing MDC. However,
unfortunately, the PGD2 receptor required for the epithe-
lial induction of MDC expression has yet to be identified,
although DP is a candidate receptor for the initiation of
MDC production in epithelial cells.
Recently, a novel aspect of DP in airway epithelial cells
was shown by Mandal et al. [5]. They demonstrated that
uteroglobin (UG)-deficient mice had elevated levels of
PGD2 in BALF and increased COX-2 gene expression in
epithelial cells. They also found that DP signaling was
mediated via p38 MAP kinase (MAPK), p44/42 MAPK,
and protein kinase C (PKC) pathways in a cell type-specif-
ic manner, leading to the activation of nuclear factor (NF)-
KB, which then stimulated COX-2 expression.UG as also
found to bind PGD2, block DP signaling, inhibit NF-KB
activation, and, consequently, suppress COX-2 gene
expression. These studies demonstrated that DP signaling
mediated allergic inflammatory responses by activating
NF-KB, which stimulated COX-2 expression. This phe-
nomenon is also observed in fibroblasts and smooth mus-
cle cells. Thus, in asthma, DP augments the production of
COX-2 metabolites of arachidonic acid, including PGD2, in
airway epithelial cells by an autocrine mechanism, result-
ing in their local accumulation and further production of
chemokines. UG thus appears to be a key component of
an innate homeostatic mechanism, acting to prevent stim-
ulation of an allergen-induced, DP-mediated inflammato-
ry response (Fig. 2).
Role of PGD2 in inflammatory cell functions (mast
cells, eosinophils, and basophils)
TH2 cells play an important role in allergic disease by
organizing the characteristic inflammatory response,
involving mast cells, basophils, and eosinophils. These
inflammatory cells also produce TH2 type cytokines, indi-
cating that these cells and TH2 cells interact to promote
TH2 type inflammation in asthma. While the above studies
suggest an important role for PGD2 in asthma pathogene-
sis, DP suppresses mast cell activation. Chan et al. [66]
collected rat peritoneal mast cells and examined the
effects on anti-IgE-induced histamine release of agonists
specific to various types of prostanoid receptors. They
found that several prostanoid agonists inhibited histamine
release; BW 245C and ZK 118182 were the most potent.
Based on these findings, they suggested that developing
highly specific agonists for the mast cell DP receptor
might improve the management of allergic diseases, such
as asthma. In contrast, Matsuoka et al. [30] showed that
the net action of DP in allergic asthma appears to be facili-
tative, given that DP is present. Strong evidence support-
ing a role for CRTH2 in mast cells is lacking, although the
receptor is expressed. In contrast, activating CRTH2
induces migration of murine mast cells, based on the
upregulation of CD23 and CD30 on the cell surface.
Eosinophils express both DP and CRTH2, which inter-
act to regulate cellular responses to PGD2. Previous stud-
ies have revealed that CRTH2 mediates eosinophil chemo-
taxis induced by mast cell products [34]. The receptor
directly responsible for stimulating eosinophil migration
appears to be CRTH2, not DP [16]. Gervais et al. [21]
found that DK PGD2, a CRTH2 agonist, stimulated
chemokinesis and degranulation of eosinophils, whereas
BW 245C did not. CRTH2 activation also leads to changes
in the shape of eosinophils, chemotaxis, enhanced chemo-
tactic responsiveness to other chemoattractants, and
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degranulation [21,22,38,39], whereas DP activation is
linked to eosinophil apoptosis [21], hich is delayed by BW
245C but not DK-PGD2. However, inhibiting DP with the
selective antagonist BW A868C resulted in markedly
enhanced CRTH2-mediated activation, as assessed by an
increase in CD11b expression on exposure to PGD2 [22].
Novel effects of PGD2 on eosinophils have been reported
by Mesquita-Santos et al. [67]. They showed that adminis-
tering PGD2 to mice enhanced leukotrienes (LT) C4 pro-
duction by inducing lipid body-driven LTC4 synthesis,
dependant on the synergistic activity of endogenous
eotaxin, acting via the CCR3 receptor.
Opposing effects of DP and CRTH2 on cell function
have also been observed in basophils, circulating leuko-
cytes that are particularly relevant during the late phase of
the allergic response and for asthmatic inflammation [24].
CRTH2 signaling is responsible for mobilizing intracellu-
lar Ca
2+ in basophils, upregulating CD11b and CD203c
expression, and enhancing IgE-mediated basophil
degranulation [68]. Conversely, DP activation inhibits
basophil migration and IgE-mediated degranulation.
Thus, it seems that activating basophils and eosinophils,
balanced by PGD2 via the dual receptor system, plays an
important role in asthma.
According to CRTH2 and DP studies, these two receptor
subtypes may collaborate in the activation and accumula-
tion of inflammatory cells, such as mast cells, eosinophils,
and basophils, at sites of allergic inflammation (Fig. 2).
Role of the PGD2 receptor in allergic disease patho-
genesis
Recent studies have shown an accumulation of CRTH2-
positive leukocytes, including TH2 cells, eosinophils,
basophils, and mast cells, in human allergic inflammatory
regions. Furthermore, CRTH2 mRNA and protein levels
are higher in eosinophils from atopic subjects than in
those from healthy controls [69]. Consistent with the
increased number of CRTH2 receptors in eosinophils
from atopic individuals, PGD2-induced chemotaxis is sig-
nificantly higher in these cells. Increased levels of CRTH2
expression and an enhanced sensitivity of eosinophils to
PGD2 might explain the tissue eosinophilia in atopic
patients. Furthermore, the percentage of CD4
+ T cells
expressing CRTH2 in patients with AD correlates with dis-
ease severity [70-72]. Additionally, available evidence
indicates that genetic alterations in CRTH2 are related to
allergic asthma. Genetic variants of CRTH2 predispose
individuals to develop asthma. CRTH2 is associated with
severe asthma in African-American and Chinese popula-
tions [70]. Associated polymorphisms in the 3’-untrans-
lated region of CRTH2 lead to increased mRNA stability,
suggesting that CRTH2 variants are associated with high-
er degrees of bronchial hyperresponsiveness and are
causally linked to asthma [70]. These findings indicate
that higher CRTH2 expression levels and increased
responsiveness to its PGD2 ligand may be the biological
basis for the association of this receptor with asthma. In
contrast, variants of PTGDR (the gene encoding DP1) with
reduced transcriptional activity have been detected in
patients with asthma [73]. Studies in a small cohort of
patients with asthma provided evidence that these puta-
tive loss-of-function variants protect against asthma
development.
CONCLUSION
PGD2 has been recognized as an important mediator of
allergic responses. It is becoming clear that PGD2 and its
metabolites may play important roles in the pathogenesis
of allergic diseases, including asthma. Although the poten-
tial clinical benefits of modifying PGD2-related receptor
function remain unsubstantiated, many studies have pro-
vided promising evidence that these receptors are
immune and inflammatory regulators in various immune
cells. The roles of DP and CRTH2 are diverse and complex
in the allergic system. Thus, future studies into the func-
tion (s) of these receptors will likely lead to new approach-
es for the treatment and, perhaps, prevention of allergic
diseases, including asthma.
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